These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
346 related articles for article (PubMed ID: 32141667)
1. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. Heckert JM; Kipnis ST; Kumar S; Botterbusch S; Alderson A; Bennett B; Creamer C; Eads JR; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Katona BW Oncologist; 2020 Jul; 25(7):572-578. PubMed ID: 32141667 [TBL] [Abstract][Full Text] [Related]
2. Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors. Kipnis ST; Hung M; Kumar S; Heckert JM; Lee H; Bennett B; Soulen MC; Pryma DA; Mankoff DA; Metz DC; Eads JR; Katona BW JAMA Netw Open; 2021 Mar; 4(3):e212274. PubMed ID: 33755166 [TBL] [Abstract][Full Text] [Related]
3. 177Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. Ranade R; Basu S J Nucl Med Technol; 2016 Jun; 44(2):65-9. PubMed ID: 26848166 [TBL] [Abstract][Full Text] [Related]
4. Clinical Response Profile of Metastatic/Advanced Pulmonary Neuroendocrine Tumors to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE. Parghane RV; Talole S; Prabhash K; Basu S Clin Nucl Med; 2017 Jun; 42(6):428-435. PubMed ID: 28319500 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea. Shin Y; Moon BH; Ryoo BY; Chang HM; Kim KP; Hong YS; Kim TW; Ryu JS; Kim YI; Yoo C Target Oncol; 2024 Jan; 19(1):41-49. PubMed ID: 38108953 [TBL] [Abstract][Full Text] [Related]
6. Persistent Hematologic Dysfunction after Peptide Receptor Radionuclide Therapy with Bergsma H; van Lom K; Raaijmakers MHGP; Konijnenberg M; Kam BLBLR; Teunissen JJM; de Herder WW; Krenning EP; Kwekkeboom DJ J Nucl Med; 2018 Mar; 59(3):452-458. PubMed ID: 28775205 [TBL] [Abstract][Full Text] [Related]
8. Safety and Effectiveness of 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy After Regional Hepatic Embolization in Patients With Somatostatin-Expressing Neuroendocrine Tumors. Hamiditabar M; Ali M; Bolek L; Vahdati G; Tworowska I; Delpassand ES Clin Nucl Med; 2017 Nov; 42(11):822-828. PubMed ID: 28832377 [TBL] [Abstract][Full Text] [Related]
10. External Validation of a Clinical Score for Patients With Neuroendocrine Tumors Under Consideration for Peptide Receptor Radionuclide Therapy. Das S; Chauhan A; Du L; Thomas KE; Jacob A; Schad A; Jain S; Jessop A; Shah C; Eisner D; Cardin DB; Ciombor KK; Goff LW; Bradshaw M; Delbeke D; Sandler M; Ramirez RA; Berlin J JAMA Netw Open; 2022 Jan; 5(1):e2144170. PubMed ID: 35044469 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of peptide receptor radionuclide therapy (PRRT) in advanced metastatic bronchial neuroendocrine tumours (NETs). Mirvis E; Toumpanakis C; Mandair D; Gnanasegaran G; Caplin M; Navalkissoor S Lung Cancer; 2020 Dec; 150():70-75. PubMed ID: 33075738 [TBL] [Abstract][Full Text] [Related]
12. Repeat Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors: A NET Center of Excellence Experience. Grewal US; Loeffler BT; Paschke A; Dillon JS; Chandrasekharan C J Gastrointest Cancer; 2024 Sep; 55(3):1165-1170. PubMed ID: 38780680 [TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of peptide receptor radionuclide therapy in neuroendocrine tumors: A single center experience. Sukrithan V; Armbruster H; Rogers S; Vogt SM; Grenade C; Verschraegen C; Zhou Y; Goyal A; Natwa M; Hussein A; Barr H; Konate D; Batdorf R; Brown A; Williams B; Zhao S; Wei L; Xu M; Shah MH; Konda B PLoS One; 2024; 19(5):e0298824. PubMed ID: 38748739 [TBL] [Abstract][Full Text] [Related]
14. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective. Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203 [TBL] [Abstract][Full Text] [Related]
15. Evaluation of Liver and Renal Toxicity in Peptide Receptor Radionuclide Therapy for Somatostatin Receptor Expressing Tumors: A 2-Year Follow-Up. Duan H; Ferri V; Fisher GA; Shaheen S; Davidzon GA; Iagaru A; Mari Aparici C Oncologist; 2022 Jun; 27(6):447-452. PubMed ID: 35641196 [TBL] [Abstract][Full Text] [Related]
16. PRRT genomic signature in blood for prediction of Bodei L; Kidd MS; Singh A; van der Zwan WA; Severi S; Drozdov IA; Cwikla J; Baum RP; Kwekkeboom DJ; Paganelli G; Krenning EP; Modlin IM Eur J Nucl Med Mol Imaging; 2018 Jul; 45(7):1155-1169. PubMed ID: 29484451 [TBL] [Abstract][Full Text] [Related]
17. Addition of Peptide Receptor Radiotherapy to Immune Checkpoint Inhibition Therapy Improves Outcomes in Neuroendocrine Tumors. Esfahani SA; De Aguiar Ferreira C; Summer P; Mahmood U; Heidari P J Nucl Med; 2023 Jul; 64(7):1056-1061. PubMed ID: 37024303 [TBL] [Abstract][Full Text] [Related]
18. Long-term results and tolerability of tandem peptide receptor radionuclide therapy with Kunikowska J; Pawlak D; Bąk MI; Kos-Kudła B; Mikołajczak R; Królicki L Ann Nucl Med; 2017 Jun; 31(5):347-356. PubMed ID: 28316066 [TBL] [Abstract][Full Text] [Related]
19. Retreatment with peptide receptor radionuclide therapy in patients with progressing neuroendocrine tumours: efficacy and prognostic factors for response. Vaughan E; Machta J; Walker M; Toumpanakis C; Caplin M; Navalkissoor S Br J Radiol; 2018 Nov; 91(1091):20180041. PubMed ID: 29513039 [TBL] [Abstract][Full Text] [Related]
20. Combination treatments to enhance peptide receptor radionuclide therapy of neuroendocrine tumours. Adant S; Shah GM; Beauregard JM Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):907-921. PubMed ID: 31492995 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]